Mayne swoops again

Generic drug manufacturer Mayne Pharma announced its second buy and capital raising in as many months. Mayne plans to raise $18 million to buy a pain relief product from global drug giant GlaxoSmithKline. The raising is priced at 29.5¢ a share, an 8 per cent discount to its last traded price. In addition to the $18 million equity placement to institutional investors and sophisticated investors, Mayne will offer a share purchase placement for up to $5 million. The $120 million purchase of private US pharmaceutical Metrics Inc will comprise $65 million of equity and $48 million debt. Madeleine Heffernan

By InvestSMART · 15 Dec 2012

By InvestSMART ·
15 Dec 2012

Share

Comments

Print

Generic drug manufacturer Mayne Pharma announced its second buy and capital raising in as many months. Mayne plans to raise $18 million to buy a pain relief product from global drug giant GlaxoSmithKline. The raising is priced at 29.5¢ a share, an 8 per cent discount to its last traded price. In addition to the $18 million equity placement to institutional investors and sophisticated investors, Mayne will offer a share purchase placement for up to $5 million. The $120 million purchase of private US pharmaceutical Metrics Inc will comprise $65 million of equity and $48 million debt.

Share this article and show your support

Proudly

Mayne swoops again

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}

{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}

{{ content.upgradeHeading.replace('{0}', user.FirstName) }}

Updating information

Please wait ...

Your membership to InvestSMART Group recently failed to renew.

You've recently updated your payment details.

Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial

Please click on the ACTIVATE button to finalise your membership

Unsuccessful registration

Forgotten password